Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth.
van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ. van Koetsveld PM, et al. Among authors: hofland lj. J Clin Endocrinol Metab. 2006 Nov;91(11):4537-43. doi: 10.1210/jc.2006-0620. Epub 2006 Aug 15. J Clin Endocrinol Metab. 2006. PMID: 16912135
Potential role of type I interferons in the treatment of pituitary adenomas.
Vitale G, Caraglia M, van Koetsveld PM, Maroni P, Marra M, Colao A, Lamberts SW, Cavagnini F, Hofland LJ. Vitale G, et al. Among authors: hofland lj. Rev Endocr Metab Disord. 2009 Jun;10(2):125-33. doi: 10.1007/s11154-008-9083-3. Epub 2008 Jul 6. Rev Endocr Metab Disord. 2009. PMID: 18604644 Review.
The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells.
Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, Arancia G, Castiglioni S, Maroni P, Bendinelli P, Piccoletti R, van Koetsveld PM, Cavagnini F, Budillon A, Abbruzzese A, Hofland LJ, Caraglia M. Vitale G, et al. Among authors: hofland lj. Biotechnol Adv. 2012 Jan-Feb;30(1):169-84. doi: 10.1016/j.biotechadv.2011.08.001. Epub 2011 Aug 17. Biotechnol Adv. 2012. PMID: 21871555
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
Faggiano A, Ramundo V, Dicitore A, Castiglioni S, Borghi MO, Severino R, Ferolla P, Crinò L, Abbruzzese A, Sperlongano P, Caraglia M, Ferone D, Hofland L, Colao A, Vitale G. Faggiano A, et al. J Cell Mol Med. 2012 Jul;16(7):1563-72. doi: 10.1111/j.1582-4934.2011.01438.x. J Cell Mol Med. 2012. PMID: 21883896 Free PMC article.
357 results